CLINICAL_TRIALS
withdrawal
· 2025-03-12
Clinical Trial Update: A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia [Phase 1, Phase 2]
Summary
A Phase 1B/2A trial evaluating the combination of ASTX727 with ASTX029 for Acute Myeloid Leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN